Monoclonal antibody · Inhibitor of connective tissue growth factor (CCN2) · developed by Kyntra Bio
Pamrevlumab is a human monoclonal antibody that binds connective tissue growth factor (CTGF), preventing its binding to its receptor and subsequent receptor activation. It is studied in unresectable pancreatic cancer and idiopathic pulmonary fibrosis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03955146 | Phase 3 | Idiopathic Pulmonary Fibrosis | Terminated | KYNB |
| NCT03941093 | Phase 3 | Pancreatic Cancer Non-resectable | Completed | KYNB |
| NCT02210559 | Phase 1/2 | Pancreatic Cancer (Unresectable) | Completed | KYNB |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Idiopathic Pulmonary FibrosisPancreatic Cancer (Unresectable)Pancreatic Cancer Non-resectable
Updated Oct 18, 2026. Something wrong or missing? Report it on the KYNB page.
See KYNB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
KYNB catalysts and pipeline →